2029, Biosimilars and Pharmaceutical Companies

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2029

Biosimilars

Pharmaceutical Companies

International life sciences regulations: How CROs, CMOs, and CDMOs are primed for advantage

Express Pharma

OCTOBER 16, 2024

Similarly, India’s pharmaceutical contract manufacturing market is expected to increase at a CAGR of 14.67 billion by 2029 (3). Manufacturing costs in India are also 30 – 35 per cent lower than those in the US and Europe (5), further sweetening the deal for global pharmaceutical companies. billion by 2030 (2).

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Pharmacist Digest

International life sciences regulations: How CROs, CMOs, and CDMOs are primed for advantage

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Stay Connected